Ruxolitinib Rutinib Cream 1.5% is a specialized topical medication designed to target inflammatory skin conditions such as eczema (atopic dermatitis) and vitiligo. Its active ingredient, Ruxolitinib, functions as a potent Janus kinase (JAK) inhibitor that effectively modulates immune system activity. By inhibiting JAK enzymes, this cream decreases inflammation and promotes repigmentation of the skin, particularly beneficial for managing vitiligo where skin depigmentation occurs. The cream is formulated for direct application on affected skin areas to maximize localized therapeutic effect while minimizing systemic exposure. Ruxolitinib Rutinib Cream is manufactured adhering to stringent quality assurance protocols to guarantee safety, potency, and consistency for dermatological treatment. It requires a healthcare provider's prescription and is best used under professional guidance to ensure proper application, prevent side effects, and achieve optimal treatment outcomes for chronic skin conditions.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ruxolitinib (1.5%) |
| Type | Topical Cream |
| Therapeutic Action | Janus kinase (JAK) enzyme inhibition to reduce inflammation and aid skin repigmentation |
| Primary Indications | Eczema (Atopic Dermatitis), Vitiligo |
| Application Method | Topical application on affected skin areas as prescribed |
| Prescription Status | Prescription Only Medicine |
| Manufacturing Quality | Produced under stringent quality standards for safety and efficacy |
| Formulation Strength | 1.5% concentration of Ruxolitinib |
| Usage Guidance | Use as directed by healthcare provider to optimize treatment and minimize side effects |
| Attributes | Description |
|---|---|
| Dosage Form | Cream |
| Concentration | 1.5% Ruxolitinib |
| Indications | Treatment of atopic dermatitis and vitiligo |
| Mechanism of Action | JAK enzyme inhibition to modulate immune responses |
| Administration Route | Topical |
| Packaging | Available in hygienic cream tubes (size varies per supplier) |
| Storage Conditions | Store at controlled room temperature, away from direct sunlight |
| Shelf Life | Typically 24 months or as per manufacturer guidelines |
| Regulatory Status | Prescription-only medication |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
It is specifically indicated for the treatment of inflammatory skin conditions such as atopic dermatitis (eczema) and vitiligo to reduce inflammation and aid in skin repigmentation.
Ruxolitinib acts as a Janus kinase (JAK) inhibitor that modulates immune activity, which reduces inflammation and helps restore pigmentation by promoting repigmentation of depigmented skin patches.
Yes, this product is a prescription-only medication and should be supplied and used under healthcare professional guidance.
The cream should be stored at controlled room temperature away from direct sunlight to preserve its stability and effectiveness.
Application over large skin areas should be done under medical supervision to avoid potential systemic absorption and side effects; typically, it is applied only to affected areas as prescribed.
Yes, the cream is manufactured under strict quality control standards ensuring safety, potency, and consistency for dermatological use.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
